Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1281-1300 of 1,743 trials

Primary Plasma Cell Leukemia: ARI0002h CAR-T Cell Therapy

We are studying a new CAR-T cell treatment for patients newly diagnosed with primary plasma cell leukemia. The trial aims to evaluate its safety, effectiveness, and impact on quality of life.

Plasma Cell Leukaemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Metoprolol for Heart Health in Duchenne Muscular Dystrophy

We are studying whether metoprolol can help prevent heart issues in boys aged 8-17 with Duchenne Muscular Dystrophy. This trial will compare its effects to a placebo alongside standard heart care.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyNeurology

Rituximab for Children with Nephrotic Syndrome

We are studying whether early treatment with rituximab helps children with idiopathic nephrotic syndrome stay in remission longer than those receiving a placebo. This trial aims to improve treatment strategies for this condition.

Nephrotic Syndrome>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesInternal MedicineNephrology

Marfan Syndrome: Valsartan for Aortic Health

We are studying whether valsartan can slow down aortic root dilatation in children and young adults with Marfan syndrome. The trial will measure changes in aortic size and related health outcomes.

Marfan SyndromeLoeys-Dietz SyndromeEhlers-Danlos Syndrome>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Heart Failure: Sertraline for Anxiety and Depression

We are studying whether sertraline can help reduce anxiety and depression symptoms in heart failure patients. The trial also looks at its effects on heart health and overall well-being.

Heart Failure with Preserved Ejection Fraction and Anxiety>2 yearsConfirmation phase (III)Investigational MedicinesCardiologyPsychiatry

Acute Ischemic Stroke: Mechanical Thrombectomy Study

We are studying whether adding a mechanical procedure to standard treatment helps patients with acute ischemic stroke due to large vessel blockage. The trial also examines safety and quality of life for participants.

Malignant Ischemic Stroke>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Kidney Transplant: Rituximab for EBV Prevention

We are studying whether early treatment with Rituximab can help prevent EBV infections and related complications in kidney transplant recipients who are EBV negative. This research aims to improve outcomes for patients receiving organs from EBV positive donors.

Epstein-Barr Virus in Kidney Transplant Patients>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesNephrology

Myelodysplastic Syndromes: Oral ASTX030 vs. Subcutaneous Azacitidine

We are studying a new oral treatment for patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. The trial aims to evaluate its safety and how it compares to the standard subcutaneous treatment.

Chronic Myelomonocytic LeukaemiaAcute Myeloid LeukaemiaMyelodysplastic Syndrome>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesHematology

Cerebral Adrenoleukodystrophy: Leriglitazone Study

We are studying whether leriglitazone can improve survival and slow disease progression in adult males with cerebral adrenoleukodystrophy. Participants will receive either the medication or a placebo to compare effects.

Adrenoleukodystrophy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNeurology

Type 1 Diabetes: Verapamil Treatment for Children

We are studying whether oral Verapamil can help preserve insulin production in children recently diagnosed with Type 1 diabetes. The trial also looks at the safety and effectiveness of this treatment in managing blood sugar levels.

Type 1 Diabetes>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesDiabetologyEndocrinology

Dupuytren's Contracture: Comparing Treatment Options

We are studying three different treatments for Dupuytren's contracture to see which one works best and is most cost-effective. This trial includes patients with mild to moderate cases and will track outcomes over several years.

Dupuytren's Contracture>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesDermatologyOrthopedics and Traumatology

Liver Cancer: Immunotherapy and Radioactive Treatment Study

We are studying the effects of two immunotherapy drugs combined with a special treatment for liver cancer. This trial aims to see if this combination improves survival and quality of life for patients with non-resectable liver cancer.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Advanced Breast Cancer: The p53 Trial

We are testing a chemotherapy treatment for patients with advanced breast cancer that has TP53 mutations. The goal is to see how well it works and to understand the safety and response of different mutation types.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Short Bowel Syndrome: Antibiotic Absorption Study

We are investigating how well certain antibiotics are absorbed in people with short bowel syndrome. This study aims to understand if these medications work effectively in this group.

Short Bowel Syndrome>2 yearsMonitoring phase (IV)Gastroenterology

Colorectal Surgery: Cefoxitin Administration Study

We are comparing two ways of giving cefoxitin to prevent infections after colorectal surgery. This study aims to find out if a continuous infusion is better than the standard method for reducing complications.

Colorectal Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInfectious DiseasesInternal MedicineOrthopedics and Traumatology

RAY121: Safety Study in Healthy Volunteers

We are testing a new treatment called RAY121 to see how safe it is and how the body reacts to it. This study helps us understand its effects before it is tested in patients.

Healthy Participants>2 yearsSafety phase (I)Neurology

CAR T-Cell Therapy for Blood Cancers

We are testing a new CAR T-cell treatment for patients with relapsed or refractory CD19-positive blood cancers. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Ovarian Cancer: ZN-c3 and Niraparib Study

We are studying the safety and effectiveness of a new drug, ZN-c3, alone and with niraparib for patients with platinum-resistant ovarian cancer. This trial aims to find better treatment options for those who have limited choices.

Recurrent Ovarian Cancer>2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cancer Imaging: GEH200520 and GEH200521 Injections

We are testing two new injections to see if they are safe and well-tolerated in patients with cancer. This study aims to improve imaging techniques for better cancer diagnosis.

Malignant Solid Tumor>2 yearsSafety phase (I)OncologyOtolaryngology

HPV Vaccine Study for Women with HPV 16/18

We are studying how the 9vHPV vaccine affects the infectivity of HPV in women who are positive for HPV types 16 and/or 18. The goal is to see if vaccination reduces the virus in cervical, anal, urine, vulvar, and oral samples.

Human Papillomavirus Infection>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases